PHARMACOGENETICS OF VINORELBINE IN MALIGNANT PLEURAL MESOTHELIOMA PATIENTS

Trial Profile

PHARMACOGENETICS OF VINORELBINE IN MALIGNANT PLEURAL MESOTHELIOMA PATIENTS

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Feb 2017

At a glance

  • Drugs Vinorelbine (Primary) ; Vinorelbine (Primary)
  • Indications Mesothelioma
  • Focus Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 09 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 09 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 20 Jul 2016 Planned End Date changed from 1 May 2014 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top